N/A
N=28
The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.
Aging
Bottom Line
View on ClinicalTrials.gov: NCT05724589 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Facial Skin Hydration — 56.043; 58.300; 55.852; 58.714 arbitrary units — p=1.000
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Epidermal Growth Factor (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Institute of Dermatology, Thailand
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Facial Skin Hydration |
56.043; 58.300; 55.852; 58.714 | 1.000 |
| PRIMARY Transepidermal Water Loss |
11.815; 8.761; 8.400; 8.160 | 0.096 |
| PRIMARY Facial Skin Elasticity (R2 Parameter Via Cutometer) |
0.596; 0.596; 0.584; 0.553 | 0.169 |
| PRIMARY Facial Skin Wrinkles |
1; 1; 1; 1 | 1.000 |
| PRIMARY Facial Melanin Index |
244.118; 246.296; 243.605; 240.660 | 1.000 |
| PRIMARY Overall Facial Skin Appearance (Photo Evaluation Using SGAIS) |
10; 18; 0; 0; 12; 16 | 1.000 |
| SECONDARY Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation |
10; 18; 0; 0; 0; 5 | — |
| SECONDARY Adverse Events |
28; 0; 0; 28; 0; 0 | — |
Summary
EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. We hypothesized that EGF would improve facial skin hydration, elasticity, pigmentation, and wrinkles.
Eligibility Criteria
Inclusion Criteria
- Thai
- Mild to moderate facial skin condition, as measured by 1-2 points on the hyperpigmentation status scale or 2-3 points on the wrinkle severity grading scale.
Exclusion Criteria
- Use of lotions or skin care products containing ingredients such as vitamin A/C, hydroquinone, or anti-aging agents.
- Sunbathing
- Hypersensitivity to serum components
- Pregnancy and breast-feeding
- Active skin diseases such as eczema or atopic dermatitis at the application site
Data sourced from ClinicalTrials.gov (NCT05724589). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.